دورية أكاديمية
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
العنوان: | Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial |
---|---|
المؤلفون: | Buti, M., Flisiak, R., Kao, J. . H., Chuang, W. . L., Streinu cercel, A., Tabak, F., Calistru, P., Goeser, T., Rasenack, J., Horban, A., Davis, G. L., Alberti, A., Pol, S., Orsenigo, R., Brass, C., MAZZELLA, GIUSEPPE |
المساهمون: | Buti, M., Flisiak, R., Kao, J. -. H., Chuang, W. -. L., Streinu-cercel, A., Tabak, F., Calistru, P., Goeser, T., Rasenack, J., Horban, A., Davis, G. L., Alberti, A., Mazzella, G., Pol, S., Orsenigo, R., Brass, C. |
سنة النشر: | 2015 |
المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
مصطلحات موضوعية: | alisporivir, antiviral therapy, genotype 1, hepatitis C viru, host-targeting agent, Adult, Aged, Antiviral Agent, Cyclosporine, Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reaction, Female, Hepatitis C, Chronic, Human, Interferon-alpha, Male, Middle Aged, Placebo, Ribavirin, Salvage Therapy, Treatment Outcome, Viral Load, Young Adult, Hepatology, Infectious Disease, Virology |
الوصف: | Alisporivir (ALV) is an oral, investigational host-targeting agent, with pangenotypic activity against hepatitis C virus (HCV). This randomized, double-blind, placebo-controlled, Phase II study explored the efficacy and safety of ALV with peginterferon-α2a/ribavirin (PR) in patients with chronic HCV genotype 1 infection in whom prior PR had failed (43% relapsers, 34% null responders and 23% partial responders). Four-hundred-and-fifty-nine patients were randomized (1:1:1:1) to ALV 600 mg once daily (QD), ALV 800 mg QD, ALV 400 twice daily (BID) or placebo plus PR for 48 weeks. When the global ALV trial programme was put on clinical hold, all patients in this study had received ≥31 weeks of randomized treatment; patients completed 48 weeks on PR alone. All ALV groups demonstrated superior rates of complete early virologic response (cEVR; primary endpoint) vs PR alone (P ≤ 0.0131), with highest cEVR rate seen with ALV 400 mg BID (74% vs 36% with PR alone; P < 0.0001). Respective SVR12 rates (key secondary endpoint) were 65% vs 26% in prior relapsers, 63% vs 5% in partial responders and 68% vs 3% in null responders. In patients who received >40 weeks of randomized treatment, the SVR12 rate was 89% for ALV 400 mg BID vs 30% for PR alone (P = 0.0053). Rates of viral breakthrough and relapse were lowest with ALV 400 mg BID. One case of pancreatitis (fully recovered) occurred with ALV/PR. Common AEs were headache, fatigue, anaemia, neutropenia and nausea. Hypertension was infrequent, but more common with ALV. ALV merits further investigation in interferon-free regimens in combination with direct-acting antiviral agents. |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | STAMPA |
اللغة: | English |
العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/25412795; info:eu-repo/semantics/altIdentifier/wos/WOS:000355669400005; volume:22; issue:7; firstpage:596; lastpage:606; numberofpages:11; journal:JOURNAL OF VIRAL HEPATITIS; http://hdl.handle.net/11585/609648Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84930332667; www.blackwell-science.com/jvh |
DOI: | 10.1111/jvh.12360 |
الإتاحة: | https://doi.org/10.1111/jvh.12360Test http://hdl.handle.net/11585/609648Test |
رقم الانضمام: | edsbas.786C31BF |
قاعدة البيانات: | BASE |
ResultId |
1 |
---|---|
Header |
edsbas BASE edsbas.786C31BF 792 3 Academic Journal academicJournal 792.1474609375 |
PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.786C31BF&custid=s6537998&authtype=sso |
FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1111/jvh.12360# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Buti%2C+M%2E%22">Buti, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Flisiak%2C+R%2E%22">Flisiak, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Kao%2C+J%2E+%2E+H%2E%22">Kao, J. . H.</searchLink><br /><searchLink fieldCode="AR" term="%22Chuang%2C+W%2E+%2E+L%2E%22">Chuang, W. . L.</searchLink><br /><searchLink fieldCode="AR" term="%22Streinu+cercel%2C+A%2E%22">Streinu cercel, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Tabak%2C+F%2E%22">Tabak, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Calistru%2C+P%2E%22">Calistru, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Goeser%2C+T%2E%22">Goeser, T.</searchLink><br /><searchLink fieldCode="AR" term="%22Rasenack%2C+J%2E%22">Rasenack, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Horban%2C+A%2E%22">Horban, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Davis%2C+G%2E+L%2E%22">Davis, G. L.</searchLink><br /><searchLink fieldCode="AR" term="%22Alberti%2C+A%2E%22">Alberti, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Pol%2C+S%2E%22">Pol, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Orsenigo%2C+R%2E%22">Orsenigo, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Brass%2C+C%2E%22">Brass, C.</searchLink><br /><searchLink fieldCode="AR" term="%22MAZZELLA%2C+GIUSEPPE%22">MAZZELLA, GIUSEPPE</searchLink> ) Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Buti, M.<br />Flisiak, R.<br />Kao, J. -. H.<br />Chuang, W. -. L.<br />Streinu-cercel, A.<br />Tabak, F.<br />Calistru, P.<br />Goeser, T.<br />Rasenack, J.<br />Horban, A.<br />Davis, G. L.<br />Alberti, A.<br />Mazzella, G.<br />Pol, S.<br />Orsenigo, R.<br />Brass, C. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2015 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22alisporivir%22">alisporivir</searchLink><br /><searchLink fieldCode="DE" term="%22antiviral+therapy%22">antiviral therapy</searchLink><br /><searchLink fieldCode="DE" term="%22genotype+1%22">genotype 1</searchLink><br /><searchLink fieldCode="DE" term="%22hepatitis+C+viru%22">hepatitis C viru</searchLink><br /><searchLink fieldCode="DE" term="%22host-targeting+agent%22">host-targeting agent</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Antiviral+Agent%22">Antiviral Agent</searchLink><br /><searchLink fieldCode="DE" term="%22Cyclosporine%22">Cyclosporine</searchLink><br /><searchLink fieldCode="DE" term="%22Double-Blind+Method%22">Double-Blind Method</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Therapy%22">Drug Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Combination%22">Combination</searchLink><br /><searchLink fieldCode="DE" term="%22Drug-Related+Side+Effects+and+Adverse+Reaction%22">Drug-Related Side Effects and Adverse Reaction</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatitis+C%22">Hepatitis C</searchLink><br /><searchLink fieldCode="DE" term="%22Chronic%22">Chronic</searchLink><br /><searchLink fieldCode="DE" term="%22Human%22">Human</searchLink><br /><searchLink fieldCode="DE" term="%22Interferon-alpha%22">Interferon-alpha</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Placebo%22">Placebo</searchLink><br /><searchLink fieldCode="DE" term="%22Ribavirin%22">Ribavirin</searchLink><br /><searchLink fieldCode="DE" term="%22Salvage+Therapy%22">Salvage Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22Viral+Load%22">Viral Load</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatology%22">Hepatology</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+Disease%22">Infectious Disease</searchLink><br /><searchLink fieldCode="DE" term="%22Virology%22">Virology</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Alisporivir (ALV) is an oral, investigational host-targeting agent, with pangenotypic activity against hepatitis C virus (HCV). This randomized, double-blind, placebo-controlled, Phase II study explored the efficacy and safety of ALV with peginterferon-α2a/ribavirin (PR) in patients with chronic HCV genotype 1 infection in whom prior PR had failed (43% relapsers, 34% null responders and 23% partial responders). Four-hundred-and-fifty-nine patients were randomized (1:1:1:1) to ALV 600 mg once daily (QD), ALV 800 mg QD, ALV 400 twice daily (BID) or placebo plus PR for 48 weeks. When the global ALV trial programme was put on clinical hold, all patients in this study had received ≥31 weeks of randomized treatment; patients completed 48 weeks on PR alone. All ALV groups demonstrated superior rates of complete early virologic response (cEVR; primary endpoint) vs PR alone (P ≤ 0.0131), with highest cEVR rate seen with ALV 400 mg BID (74% vs 36% with PR alone; P < 0.0001). Respective SVR12 rates (key secondary endpoint) were 65% vs 26% in prior relapsers, 63% vs 5% in partial responders and 68% vs 3% in null responders. In patients who received >40 weeks of randomized treatment, the SVR12 rate was 89% for ALV 400 mg BID vs 30% for PR alone (P = 0.0053). Rates of viral breakthrough and relapse were lowest with ALV 400 mg BID. One case of pancreatitis (fully recovered) occurred with ALV/PR. Common AEs were headache, fatigue, anaemia, neutropenia and nausea. Hypertension was infrequent, but more common with ALV. ALV merits further investigation in interferon-free regimens in combination with direct-acting antiviral agents. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => STAMPA ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/25412795; info:eu-repo/semantics/altIdentifier/wos/WOS:000355669400005; volume:22; issue:7; firstpage:596; lastpage:606; numberofpages:11; journal:JOURNAL OF VIRAL HEPATITIS; http://hdl.handle.net/11585/609648; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84930332667; www.blackwell-science.com/jvh ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1111/jvh.12360 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1111/jvh.12360<br />http://hdl.handle.net/11585/609648 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.786C31BF ) |
RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/jvh.12360
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => alisporivir
[Type] => general
)
[1] => Array
(
[SubjectFull] => antiviral therapy
[Type] => general
)
[2] => Array
(
[SubjectFull] => genotype 1
[Type] => general
)
[3] => Array
(
[SubjectFull] => hepatitis C viru
[Type] => general
)
[4] => Array
(
[SubjectFull] => host-targeting agent
[Type] => general
)
[5] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[6] => Array
(
[SubjectFull] => Aged
[Type] => general
)
[7] => Array
(
[SubjectFull] => Antiviral Agent
[Type] => general
)
[8] => Array
(
[SubjectFull] => Cyclosporine
[Type] => general
)
[9] => Array
(
[SubjectFull] => Double-Blind Method
[Type] => general
)
[10] => Array
(
[SubjectFull] => Drug Therapy
[Type] => general
)
[11] => Array
(
[SubjectFull] => Combination
[Type] => general
)
[12] => Array
(
[SubjectFull] => Drug-Related Side Effects and Adverse Reaction
[Type] => general
)
[13] => Array
(
[SubjectFull] => Female
[Type] => general
)
[14] => Array
(
[SubjectFull] => Hepatitis C
[Type] => general
)
[15] => Array
(
[SubjectFull] => Chronic
[Type] => general
)
[16] => Array
(
[SubjectFull] => Human
[Type] => general
)
[17] => Array
(
[SubjectFull] => Interferon-alpha
[Type] => general
)
[18] => Array
(
[SubjectFull] => Male
[Type] => general
)
[19] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[20] => Array
(
[SubjectFull] => Placebo
[Type] => general
)
[21] => Array
(
[SubjectFull] => Ribavirin
[Type] => general
)
[22] => Array
(
[SubjectFull] => Salvage Therapy
[Type] => general
)
[23] => Array
(
[SubjectFull] => Treatment Outcome
[Type] => general
)
[24] => Array
(
[SubjectFull] => Viral Load
[Type] => general
)
[25] => Array
(
[SubjectFull] => Young Adult
[Type] => general
)
[26] => Array
(
[SubjectFull] => Hepatology
[Type] => general
)
[27] => Array
(
[SubjectFull] => Infectious Disease
[Type] => general
)
[28] => Array
(
[SubjectFull] => Virology
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Buti, M.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Flisiak, R.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kao, J. . H.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chuang, W. . L.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Streinu cercel, A.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tabak, F.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Calistru, P.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Goeser, T.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rasenack, J.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Horban, A.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Davis, G. L.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alberti, A.
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pol, S.
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Orsenigo, R.
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Brass, C.
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => MAZZELLA, GIUSEPPE
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Buti, M.
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Flisiak, R.
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kao, J. -. H.
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chuang, W. -. L.
)
)
)
[20] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Streinu-cercel, A.
)
)
)
[21] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tabak, F.
)
)
)
[22] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Calistru, P.
)
)
)
[23] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Goeser, T.
)
)
)
[24] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rasenack, J.
)
)
)
[25] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Horban, A.
)
)
)
[26] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Davis, G. L.
)
)
)
[27] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alberti, A.
)
)
)
[28] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mazzella, G.
)
)
)
[29] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pol, S.
)
)
)
[30] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Orsenigo, R.
)
)
)
[31] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Brass, C.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2015
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
)
)
)
)
)
|
IllustrationInfo |